Edition:
United Kingdom

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

3.66USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,970
52-wk High
$6.19
52-wk Low
$3.20

Chart for

About

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth... (more)

Overall

Beta: 2.37
Market Cap(Mil.): $221.93
Shares Outstanding(Mil.): 50.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

08 Nov 2017

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

27 Sep 2017

BRIEF-Cascadian Therapeutics Q2 loss per share $0.30

* Cascadian Therapeutics reports second quarter 2017 financial results

08 Aug 2017

BRIEF-Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe

* Cascadian Therapeutics announces positive regulatory update for tucatinib in Europe

11 Jul 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF240.40 -1.30
Roche Holding Ltd. (RO.S) CHF243.20 -0.80
GlaxoSmithKline plc (GSK.L) 1,316.50 +2.00
Eli Lilly and Co (LLY.N) $86.71 +0.04
Transgene SA (TRNG.PA) €2.61 -0.02
Puma Biotechnology Inc (PBYI.OQ) $99.60 --

Earnings vs. Estimates